Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108417 | 0.91 | TRPV1 (0.55) | TRPV1ABCG2MDM2EPHX2 | |
| SCHEMBL5102755 | 0.88 | MAPT (0.47) | TRPV1MEN1NPC1MAPTRAB9A | |
| SCHEMBL5108400 | 0.88 | TRPV1 (0.60) | TRPV1 | |
| Hydrochloric Acid SCHEMBL5139394 | 0.87 | MAPT (0.46) | TRPV1MEN1NPC1MAPTRAB9A | |
| SCHEMBL4917009 | 0.84 | TRPV1 (0.48) | TRPV1ABCG2EPHX2 | |
| SCHEMBL5113826 | 0.83 | NPC1 (0.42) | TRPV1MDM2MEN1NPC1LMNA | |
| SCHEMBL810113 | 0.83 | TRPV1 (0.44) | TRPV1ABCG2EPHX2MEN1NPC1 | |
| SCHEMBL5115543 | 0.81 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL4976316 | 0.81 | TRPV1 (0.44) | TRPV1EPHX2NPC1MAPTRAB9A | |
| SCHEMBL4915071 | 0.81 | TRPV1 (0.51) | TRPV1ABCG2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432275-B2 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432275-B2 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432275-B2 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060089354-A1 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORPORATION | 2006-04-27 | — | — | US | disclosed |
| EP-1569926-A1 | CARBOXYLIC ACID, PHOSPHATE OR PHOSPHONATE SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004055004-A1 | CARBOXYLIC ACID, PHOSPHATE OR PHOSPHONATE SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089354-A1 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | P2RX3, P2RY1, HCAR3 | TRPV1 5/4885ABCG2 267/4885MDM2 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.